Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer

Hammer, Janne H.; Basse, Linda; Svendsen, Mads Nordahl; Werther, Kim; Brünner, Nils; Christensen, Ib Jarle; Nielsen, Hans Jørgen

doi:10.1111/j.1463-1318.2005.00831.x

Cited by 17 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, no significant correlations between tissue and blood concentrations were detected for any of the studied parameters. No significant reduction of their plasma concentration after removal of the primary tumor was detected (Table 2), the levels of MMP-9 and TIMP-1 even increased after the intervention (p<0.05 and p<0.01, respectively), which is in line with previous data [4,15]. On the whole, changes in plasma protein concentrations were oppositely directed ( Fig.…”

Section: Resultssupporting

confidence: 92%

“…Thus, the expression of MMP-7 and TIMP-1 increased significantly in tumors of patients with colorectal cancer, which agrees with the important role of these proteins in the pathogenesis of this disease [3,4,8]. No pronounced changes in the expression of MMP-9 and TIMP-4 were detected, though some reports indicate high expression of MMP-9 in [6] (data were obtained by other methods).…”

Section: Resultssupporting

confidence: 84%

See 1 more Smart Citation

Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer

Короткова

Shcherbakov

et al. 2007

Bull Exp Biol Med

View full text Add to dashboard Cite

Enzyme immunoassays showed significantly elevated content of matrix metalloproteinase 7 and type 1 tissue inhibitor of metalloproteinases in tumors compared to adjacent histologically unchanged mucosa of patients with colorectal cancer; the levels of metalloproteinase 9 and type 4 tissue inhibitor of metalloproteinases were virtually the same in the tumors and mucosa. Plasma concentrations of the studied proteins did not correlate with their levels in the tumor, did not surpass the normal, and did not decease after removal of the primary tumor in the majority of patients.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Resultssupporting

confidence: 84%

Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer

Короткова

Shcherbakov

et al. 2007

Bull Exp Biol Med

View full text Add to dashboard Cite

show abstract

“…In contrast to these observations are other results, which are actually in agreement with clinical studies showing a correlation between elevated TIMP-1 expression and poor prognosis in many human cancer types (5,8), where elevated levels of TIMP-1 either had no effect on metastasis (9) or led to increased incidence (10,11) or growth (12) of primary tumors. These effects of TIMP-1 on cancer development have been attributed to its known proproliferative, antiapoptotic (5), or proangiogenic (13) activities, which are necessary but not sufficient for metastasis.…”

Section: Introductioncontrasting

confidence: 55%

Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling

Kopitz¹,

Gerg²,

et al. 2007

View full text Add to dashboard Cite

Balanced expression of proteases and their inhibitors is one prerequisite of tissue homeostasis. Metastatic spread of tumor cells through the organism depends on proteolytic activity and is the death determinant for cancer patients. Paradoxically, increased expression of tissue inhibitor of metalloproteinases-1 (TIMP-1), a natural inhibitor of several endometalloproteinases, including matrix metalloproteinases and a disintegrin and metalloproteinase-10 (ADAM-10), in cancer patients is negatively correlated with their survival, although TIMP-1 itself inhibits invasion of some tumor cells. Here, we show that elevated stromal expression of TIMP-1 promotes liver metastasis in two independent tumor models by inducing the hepatocyte growth factor (HGF) signaling pathway and expression of several metastasis-associated genes, including HGF and HGF-activating proteases, in the liver. We also found in an in vitro assay that suppression of ADAM-10 is in principle able to prevent shedding of cMet, which may be one explanation for the increase of cell-associated HGF receptor cMet in livers with elevated TIMP-1. Similar TIMP-1-associated changes in gene expression were detected in livers of patients with metastatic colorectal cancer. The newly identified role of TIMP-1 to create a prometastatic niche may also explain the TIMP-1 paradoxon. [Cancer Res 2007;67(18):8615-23]

show abstract

“…Elevated plasma TIMP -1 levels were reported to be significantly increased in colon cancer patients compared with healthy population, and they were also associated with advanced disease stage and poor prognosis 3,5,6,9–12. The aim of this study is to determine whether the TIMP-1 levels are higher in patients with rectal cancer as compared with healthy blood donors.…”

Section: Introductionmentioning

confidence: 97%

Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III

Oblak¹,

Anderluh²,

Velenik³

et al. 2011

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundThe purpose of the study was to analyse whether the levels of the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) are higher in patients with rectal cancer as compared with healthy blood donors.Patients and methods.Two hundred and seventeen patients (147 male, 70 female) with histologically confirmed non-metastatic rectal cancer (clinical stage II–III) and 45 healthy blood donors (15 male, 30 female) were included in analysis. Patient’s mean age was 66 years (range: 34–87 years) and healthy blood donor’s mean age was 35 years (range: 18–64 years). Plasma TIMP-1 concentrations were measured with an enzyme-linked immunosorbent assay (ELISA) using commercially available TIMP-1 ELISA kit. Mann-Whitney-test for independent groups was used to assess the differences of plasma TIMP-1 levels and clinicopathological parameters. Two-sided tests were used and the differences at P<0.05 were considered as statistically significant.ResultsMedian patients TIMP-1 level was 180 ng/mL (range: 22-538 ng/mL); the mean (±SD) level was 193.7 (79.5) ng/mL. The median healthy blood donors TIMP-1 level was 112 ng/mL (range: 48-211 ng/mL); the mean (±SD) level was 115 (35.7) ng/mL. TIMP-1 levels in patients with rectal cancer were statistically significantly higher than TIMP-1 levels in healthy blood donors (P<0.0001). Significant differences in TIMP-1 levels were not found comparing gender (P=0.43), but in both groups TIMP-1 levels were increased with higher age (P=0.007).ConclusionsPatients with rectal cancer had statistically significantly higher mean and median TIMP-1 level than healthy blood donors which is in accordance with the results published in other publications. These findings suggest possibility that plasma TIMP-1 levels could be used as new biological markers for early cancer detection.

show abstract

Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer

Abstract: Major surgery has considerable impact on plasma TIMP-1 levels. Intra- and post-operative changes of plasma TIMP-1 levels are independent of the surgical approach, and resection for CC does not lead to a significant decrease of plasma TIMP-1 levels within 30 days postoperatively.

Cited by 17 publications

References 22 publications

Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer

Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer

Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling

Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III

Contact Info

Product

Resources

About